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ABSTRACT 
Objective: Preparation and characterization of ketorolac tromethamine (KT)-loaded alginate/chitosan nanodispersions for ocular sustained drug 
delivery and improved transconeal permeation. 
Methods: Alginate/chitosan KT-loaded nanoparticles were formulated using different techniques; modified coaservation and ionotropic pregelation. 
The nanodispersions were evaluated for particle size, zeta potential, entrapment efficiency and in-vitro release. The formula with optimum 
physicochemical characteristics was tested for stability as well as ex-vivo transcorneal permeation in comparison to marketed eye drops (Acular®). 
Results: In both techniques, increasing the concentration of chitosan showed a significant increase in particle size. However, increased size with 
increasing the amount of alginate was significant in modified coaservation method but non-significant in ionotropic pregelation method. The ionotropic 
pregelation method generally resulted in nanoparticles with smaller sizes. The values of zeta potential were highly influenced by the alginate/chitosan 
ratio in both methods as the high amount of alginate shifted the zeta potential to be negative, and the absolute value increased by increasing its 
concentration. The entrapment of KT into nanoparticles prepared by ionotropic pregelation method was found to be significantly lower than those 
prepared by modified coaservation method. All the nanodispersions showed an initial burst release followed by a more gradual and sustained-release 
phase. Alginate NPs significantly retarded the release of KT and showed higher transcorneal permeation when compared with Acular®.  
Conclusion: Ionotropic pregelation method produced nanodispersions for all tested alginate/chitosan ratios with sustained KT release and 
improved transcorneal permeation.  
Keywords: Ketorolac tromethamine, Nanodispersions, Alginate, Chitosan, Sustained release, Permeation. 
 
INTRODUCTION 
Topical delivery of eye drops into the lower cul-de-sac is the most 
common method of drug treatment in ocular diseases. Although the 
main route for intraocular absorption is across the cornea, this route 
suffers from low drug permeability due to small surface area [1, 2]. 
During cataract surgery, the ocular tissue is traumatized, and 
inflammatory mediators are liberated via enzymes, e. g. 
Cyclooxygenases and lipoxygenase [3]. In ocular tissue, arachidonic 
acid is metabolized by cyclooxygenases to prostaglandins, which are 
the most important lipid-derived mediators of inflammation [4]. To 
control this postoperative inflammatory reaction, two main 
substance groups are topically available, corticosteroids or non-
steroidal anti-inflammatory drugs (NSAIDs), which interfere with 
the cyclooxygenase and/or lipoxygenase pathways [5]. Topical 
therapy with corticosteroids is quite common in the treatment of 
ocular inflammatory disorders, but their use is often associated with 
an increase in intraocular pressure, development of cataract and the 
risk of microbial infection [6]. Therefore, NSAIDs are widely used.  
Aqueous ocular drops of ketorolac tromethamine (KT) are effective 
and safe for topical use following cataract surgery and intra ocular 
lens implantation [7, 8]. They are also effective in reducing 
conjunctivitis with no alteration of corneal opacity [9], and do not 
increase intra ocular pressure [10]. They can be considered as a 
viable alternative to corticosteroids in treating ocular inflammation. 
The administration of eye drops for the treatment of ocular 
disorders suffers from numerous disadvantages because part of the 
drop instilled in the patient’s cul-de-sac is lost by over flow, it may 
also drain into the naso lacrimal duct and thus can cause unwanted 
systemic side effects. Therefore, frequent instillation may be 
necessary. To overcome the disadvantages of eye drops, several new 
approaches have been tried including the use of bio-adhesive 
polymers, liposomes and nanoparticles which may improve the 
ocular bioavailability of the drug. 
Nanoparticles (NPs) are colloidal particles, with sizes ranging from 
10–1000 nm [11, 12]. Polymeric NPs offer some specific advantages 
over liposomes as they increase the stability of drugs and processes 
useful controlled release properties [13]. Cationic polymers may 
have good muco adhesive properties due to their ability to develop 
electrostatic interaction with the negative charges of the mucus [14]. 
Among the various types of chitosan–polyanion complexes, the 
combination of chitosan (CS) and sodium alginate (ALG) are 
considered to be the most interesting for colloidal carrier 
systems [15]. CS is a nontoxic, hydrophilic and biocompatible 
cationic polysaccharide. It has very good muco adhesive and 
antibacterial properties; in addition it enhances the membrane 
permeability [16]. ALG is a natural and hydrophilic polymer 
suitable for the entrapment of water soluble drugs [17]. The 
polyelectrolyte complex formed through the ionic gelation via 
interaction between the carboxyl groups of alginate and the 
amine groups of chitosan [18]. 
In the present study, a challenge has been made to develop KT-
loaded ALG/CS nanodispersions using different techniques with the 
aim to sustain the release of KT and to improve its transcorneal 
permeation. 
MATERIALS AND METHODS 
Materials 
Ketorolac tromethamine was kindly supplied from European 
Egyptian Pharmaceutical Industrial Company, Egypt. Chitosan 
(low Mw, viscosity, 20 cps, degree of deacetylation 85%) and 
sodium alginate were purchased from Sigma-Aldrich Chemical 
Company, USA. Disodium hydrogen phosphate, potassium 
dihydrogen phosphate, sodium chloride, and calcium chloride 
were purchased from Adwik, El Nasr Pharmaceutical Chemical 
Company, Egypt. 
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Methodology 
Preparation of ALG/CS nanoparticles 
ALG/CS nanoparticles were prepared by two methods. 
Modified coaservation method 
ALG/CS nanoparticles were prepared according to the modified 
coaservation method suggested by Calvo et al. [13]. Aqueous solutions 
of ALG were prepared in different concentrations (0.2, 0.4 and 0.6%). 
CS was dissolved in 1% acetic acid to form different concentrations 
(0.1, 0.2 and 0.3%) to which one ml of KT solution (75 mg/ml) was 
added with stirring. Four milliliters of ALG solution were sprayed into 
10 ml of CS solution under continuous magnetic stirring at 1000 rpm 
for 30 min. The formulations which appeared as opalescent 
dispersions were left overnight at room temperature for complete 
formation of NPs and stored in the refrigerator until use. 
Ionotropic pregelation method 
It is a two-step method adapted from Rajaonarivony’s method of 
preparing alginate–poly-Lysine NPs [19]. Solutions of CS, ALG and 
CaCl2 in different concentrations were first prepared; CS was 
dissolved in 1% acetic acid followed by pH adjustment to 5.5 using 
NaOH; ALG was dissolved in distilled water, and pH was adjusted to 
5.0–5.3 using HCl; CaCl2 was dissolved in distilled water at neutral 
pH. The first step in the method is the formation of calcium alginate 
pre-gel by adding 6 ml of different concentrations (0.5, 0.75 and 1%) 
of aqueous CaCl2 solution to 10 ml ALG solution (0.2, 0.4 and 0.6%) 
containing 5 mg/ml of KT, while stirring at 400 rpm for 30 min. The 
second step was the addition of 4 ml of CS solution (0.1, 0.2 and 
0.3%) to the resultant calcium alginate pre-gel with continuous 
stirring for another 30 min. The resultant opalescent dispersions 
were equilibrated overnight at room temperature to allow the 
formation of uniform nanoparticles.  
Evaluation of KT-loaded nanoparticles 
Particle size and polydispersity index 
The mean particle size and size distribution of freshly prepared 
nanoparticle dispersions were determined using a Malvern Zetasizer 
2000 (Malvern Instruments Ltd., UK). Light scattering was 
monitored at a 90 o angles and a temperature of 25 oC with 
polystyrene bead was used as a standard to check instrument 
performance. The measurements were performed after diluting 
samples by 100-fold with water at the ambient temperature. The 
predetermined refractive index of the different formulae was 
incorporated into the computer software of the Zetasizer, which 
calculated the mean particle size and polydispersity from intensity. 
Zeta potential 
The zeta potential was determined using Zetasizer 2000 (Malvern 
Instruments Ltd., UK). The nanocarrier dispersion (0.25 ml) was 
diluted with 0.001 M KCl and placed in the electrophoretic cell. The 
zeta-potential values were calculated from the mean electrophoretic 
mobility values. 
Entrapment efficiency (EF %) 
The amount of drugs entrapped in the NPs was determined by 
calculating the difference between the total amount of KT used to 
prepare the NPs and the amount of non-entrapped drugs remaining 
dissolved in the aqueous suspending medium. Five milliliters of KT-
loaded NPs suspensions were centrifuged at 13 500 rpm and 4 oC for 
60 min (cooling ultracentrifuge; Sigma, Germany) to separate the 
drug loaded nanoparticles from the aqueous medium (supernatant) 
containing unloaded KT. The supernatant was analyzed for the free 
drug spectro photometerically at 321 nm (UV spectrophotometer; 
Shimaduz, USA). The drug entrapment efficiency (EF %) of NPs was 
calculated as indicated below [20]. 
EF% = A− B
A
x	100 
Where A is the total amount of drug in the nano dispersion and B is 
the free amount of drug in the supernatant. 
In vitro drug release studies 
The in vitro release test was performed using the USP dissolution 
apparatus (USP rotating paddle dissolution apparatus, Schleuniger 
pharmaton, Switzerland). Samples of one ml of KT-loaded NPs 
dispersions were placed in glass cylindrical tubes (2.5 cm in 
diameter and 10 cm in length) with one end tightly covered with a 
cellophane membrane soaked overnight in phosphate buffer saline 
(PBS), pH 7.4 and the other end attached to the shaft of the USP 
dissolution tester apparatus, instead of the baskets. The 
formulations were immersed in 50 ml of PBS (pH 7.4). The release 
study was carried out at 37±0.5 oC, and the stirring shafts rotated at 
a speed of 25 rpm. Aliquots of two ml of the release mediums were 
collected at predetermined time intervals of 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 
4, 5, 6 and 7 h and replaced with equal volumes of PBS. The collected 
samples were analyzed for drug content spectrophotometrically at 
321 nm against the samples withdrawn at a respective time 
intervals from plain nanocarrier dispersions treated by the same 
manner. The experiment was performed in triplicate, and the 
percentage released of KT was calculated. 
The mean dissolution rate (MDR) was calculated for each 
nanodispersion formulation according to the following equation:  
MDR=	∑ ∆Mj∆t
n
j1  +/n 
Where n is the number of dissolution sample times, Δ t is the time at 
midpoint between t and t−1 [calculated with (t+t−1)/2] and Δ Mj is 
the additional amount of drug dissolved between tj and t−1. 
Kinetic analysis of the release data 
The in vitro release profiles were tested for their kinetic behavior in 
order to establish the kind of mechanism possibly involved in KT 
release from the NPs. The data were analyzed according to zero-
order, first-order, Higuchi model as well as Korsmeyer-Peppas 
model. The preference of a certain mechanism was based on the 
determination coefficient (R2). 
Freeze drying  
Aliquots of three different batches of the optimized formulation 
were freeze-dried to study the FT-IR spectroscopy of the 
nanoparticles. The KT-loaded ALG/CS NPs were collected by 
centrifugation (cooling centrifuge, Sigma, Germany) at 13 500 rpm 
and 4 °C for 30 min and the residues were washed twice by distilled 
water. The residues were frozen in liquid nitrogen and lyophilized 
(Heto Drywinner, Thermo Scientific, USA) for 48 h at 120 °C, at a 
pressure of 0.05 mmHg. 
Fourier transform infra-red (FT-IR) spectroscopy  
FT-IR spectrum was recorded for KT, ALG, CS and the freeze-dried 
KT-loaded ALG/CS nanoparticles using FT-IR spectroscopy (Genesis 
II Mattson, USA). A total of 2% w/w of sample, with respect to the 
potassium bromide (KBr) disc, was mixed with dry KBr. The mixture 
was ground to the fine powder using an agate mortar before 
compressing into KBr disc under a hydraulic press of 10 000 psi. 
Each KBr disc was scanned at 4 mm/s at a resolution of 2 cm over a 
wave number region of 400–4000 cm using IR solution software, 
and the characteristic peaks were recorded for different samples. 
Nanoparticles morphology 
The morphologic examination of NPs was performed by 
transmission electron microscopy (TEM; CM12; Philips, USA). The 
selected NP dispersion was dropped onto Formvar-coated copper 
grids and after complete drying the samples were stained using 2% 
w/v phosphotungstic acid.  
Ex vivo transcorneal permeation 
Transcorneal permeation study of the optimum nano dispersion was 
carried out as previously described in the release study using a 
freshly excised bovine cornea as membrane instead of cellophane. 
The corneal area available for diffusion was 0.78 cm2. The receptor 
compartment was filled with 50 ml PBS (pH 7.4) and was kept at 37 
°C± 0.5 with constant stirring at 50 rpm. Permeation study was 
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continued for three hours, and samples were withdrawn at 
predetermined time intervals, 15, 30, 60, 90, 120, 150 and 180 min 
and were analyzed for KT spectr photometerically at 321 nm.  
At the end of the experiment, each cornea was weighed and soaked 
in one ml methanol, dried overnight and reweighed. From the 
difference in weights between hydrated and dried cornea, corneal 
hydration was calculated. 
Stability studies 
Samples of the selected optimum nanoparticle dispersion were 
sealed in 30 ml amber glass vials and stored for six months at 
different temperatures (4 oC and 25 oC). The stored samples were 
visually inspected for settling and changing in color. The entrapment 
efficiency as well as the mean particle size and pH was determined 
and compared to the freshly prepared samples. 
Statistical analysis 
Student t-test was used to analyze data of two groups obtained in 
different experiments at the 0.05 level of significance by Graph Pad 
Instate-3 software. One-way analysis of variance (ANOVA) analyzed 
all other data obtained for more than two groups by the same 
software. 
RESULTS AND DISCUSSION 
NPs consisting of ALG and CS were prepared by two different 
techniques namely modified coaservation and ionotropic 
pregelation. The freshly prepared nanodispersions were evaluated 
for particle size, zeta potential, entrapment efficiency and in vitro 
drug release. FT-IR spectroscopy, morphology, ex vivo transcorneal 
permeation and stability study were done for the selected 
formulation with optimum characteristics. 
Evaluation of the preparations 
The composition and physicochemical properties of ALG/CS 
dispersions prepared by modified coaservation method and 
ionotropic pregelation method are shown in Table 1 and 2, 
respectively. 
Following modified coacervation method, not all ALG/CS ratios 
resulted into the formation of colloidal dispersions. From Table 1, it 
is obvious that formulations in which CS amount exceeded largely 
that of alginate (A4, A7 and A8) yielded clear solutions and 
therefore, were excluded from the study. In the case of ionotropic 
pregelation method, an opalescent colloidal dispersion was 
observed for all ALG/CS combinations (Table 2). 
  
Table 1: Composition and physical appearance of CS/ALG formulations prepared according to modified coaservation method 
code Composition Physical appearance 






A1 0.1 0.2 0.07 0.06 0.13 √ 
A2 0.1 0.4 0.07 0.11 0.18 √ 
A3 0.1 0.6 0.07 0.17 0.24 √ 
A4 0.2 0.2 0.14 0.06 0.2 × 
A5 0.2 0.4 0.14 0.11 0.25 √ 
A6 0.2 0.6 0.14 0.17 0.31 √ 
A7 0.3 0.2 0.21 0.06 0.27 × 
A8 0.3 0.4 0.21 0.11 0.32 × 
A9 0.3 0.6 0.21 0.17 0.38 √ 
N. B: ×, clear solution; √, opalescent dispersion, * Concentration in polymer solution, # Concentration in the final formulation (total volume = 14 ml). 
 
Table 2: Composition and physical appearance of CS/ALG formulations prepared by ionotropic pregelation method 
code Composition Physical 










P1 0.1 0.2 0.5 0.02 0.1 0.15 0.12 √ 
P2 0.1 0.4 0.5 0.02 0.2 0.15 0.22 √ 
P3 0.1 0.6 0.5 0.02 0.3 0.15 0.32 √ 
P4 0.1 0.2 0.75 0.02 0.1 0.225 0.12 √ 
P5 0.1 0.2 0.1 0.02 0.1 0.3 0.12 √ 
P6 0.2 0.2 0.5 0.04 0.1 0.15 0.14 √ 
P7 0.3 0.2 0.5 0.06 0.1 0.15 0.16 √ 
√: opalescent dispersion, * Concentration in polymer solution, # Concentration in the final formulation (total volume = 20 ml) 
 
Particle size  
For nanoparticles prepared by modified coaservation method, 
increasing either CS or ALG percentage resulted in a significant 
increase in particle size (p<0.05) (table 3). This was expected since 
higher polymer concentration is accompanied by a higher amount of 
polymer forming the core of the particle, thus, larger particles are 
formed [21]. 
However, this effect was not observed in ionotropic pregelation 
method. Keeping the concentration of CS and CaCl2 constant and 
increasing the percentage of ALG (P1, P2 and P3) did not 
significantly affect particle size (p>0.05). Nevertheless, keeping ALG 
constant and increasing either CaCl2 (P1, P4, P5) or CS (P1, P6, P7) 
significantly (p<0.05) increased particle size, which would probably 
indicate that the bulk of nanoparticle matrix is mainly composed of 
both CS and CaCl2 [22]. 
From Table 3 and 4, it is clear that the method of preparation 
significantly (p<0.05) affected the particle size. When (A1/A3/A6) 
and (P1/P2/P3) were compared (fig. 1), as they contain close total 
polymer percentages, respectively, it is obvious that the ionotropic 
pregelation method resulted in smaller particle sizes despite the 
additional presence of calcium ions, which contribute to the 
formation of the particle core. This result may be attributed to that, 
although ALG can be complex with CS alone and can form 
nanoparticles through formation of a simple polyelectrolyte 
complex, the formation of a pre-gel phase between Ca2+ions and 
alginate, allow the formation of nanoparticles with increased 
compact structure [21].  
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Fig. 1: Effect of method of preparation on the particle size of 
alginate NPs containing close total polymers percentages 
(mean±SD, n=3) (A1: 0.13, P1: 0.12, A3: 0.24, P2: 0.22, A6: 0.31 
and P3: 0.32%) 
 
Zeta potential 
The values of zeta potential are highly influenced by the ALG/CS 
ratio because the zeta potential of the ALG/CS nano reservoir system 
is dependent on the availability of total protonated NH3+groups on 
CS and their neutralization with COO-groups of ALG. In case of the 
coaservation method, as shown in Table 3, the formulations A1, A5 
and A9 in which the percentage of CS exceeded that of ALG showed a 
positive zeta potential. When ALG exceeded CS (A2, A3 and A6) the 
formulations showed negatively charged zeta potential, which 
indicates that carboxylate groups of ALG are not sufficiently 
neutralized by the protonated amino groups of CS. 
However, for nanoparticles formulated by ionotropic pregelation 
method, Ca2+ions also play a role in the overall charge on the 
particles. It is believed that, the nanoparticles produced by this 
technique are generally characterized by core/shell structure. The 
core is composed of complexed segments (a complex between the 
protonized–NH3+of CS, Ca+2ions of CaCl2 and COO-groups of ALG), 
while excess Ca+2ions, that are not incorporated into the 
polyelectrolyte complex, are segregated in the outer shell and give 
the nano particles surface an overall positive charge [23].  
Therefore, in order to interpret these results, the total amount of CS 
together with CaCl2 should be regarded in comparison to the amount 
of ALG in each formula. It is to be noted that, formulae which 
contained higher percentages of alginate (P2 and P3, except for P1) 
revealed a negative zeta potential. P1 showed a negative zeta 
potential with small value (-3.7 mV) despite having higher alginate 
content and this probably because the amounts of CS and CaCl2 were 
still insufficient to interact with all carboxyl groups of alginate. 
However, increasing the concentration of CaCl2 (P4 and P5) or 
increasing the concentration of CS (P6 and P7) shifted the zeta 
potential to positive values. 
Entrapment efficiency (EF %) 
No significant differences were observed between the EF% of the 
different formulae prepared by the same method (Tables 3 and 4). 
This finding indicates that using different concentrations of 
polymers in preparation of NPs did not significantly (p>0.05) 
influence the entrapment efficiency of KT. However, the method of 
preparation obviously affected the EF%. In general, the entrapment 
of KT into ALG/CS nanoparticles prepared by ionotropic pregelation 
method was found to be significantly (p<0.05) lower than those 
prepared by modified coaservation method. This may be explained 
upon the basis that, at higher concentrations of the components that 
make the bulk of the nanoparticle’s matrix, less volume is available 
for drug encapsulation. Thus, the presence of CaCl2 that makes the 
bulk of the NPs and causes the particles to be smaller and denser 
decreased the entrapment of the drug.  
The EF% of (A1/A3/A6) and (P1/P2/P3) were compared as they 
contain close total polymer percentages, respectively, and the effect of 
CaCl2 on reducing EF% could be obviously observed, as shown in fig. 2. 
 
 
Fig. 2: Effect of method of preparation on entrapment efficiency 
of alginate NPs containing close total polymers percentages 
(mean±SD, n=3) (A1: 0.13, P1: 0.12, A3: 0.24, P2: 0.22, A6: 0.31 
and P3: 0.32%)
 
Table 3: Physicochemical properties of KT-loaded ALG/CS nanoparticles prepared by modified coaservation method 
Formulation 
Code 




Zeta potential  
(mV)±SD 




A1 493.2±22.5 0.44 13.7±1.40 41.88±2.54 10.45 
A2 704.3±18.9 0.67 -10.7±0.56 37.27±5.10 10.52 
A3 1354±37.3 0.45 -16.4±0.93 36.62±1.87 ND 
A5  905.1±25.1 0.74 12.3±1.10 47.53±3.64 9.32 
A6 1401±29.9 0.13 -14.6±0.79 44.38±2.94 ND 
A9 1634.4±21.4 0.93 11.8±0.82 36.18±2.55 ND 
ND: not determined 
 
Table 4: Physicochemical properties of KT-loaded ALG/CS nanoparticles prepared by ionotropic pregelation method 
Formulation 
Code 




Zeta potential  
(mV)±SD 




P1 131.2±10.6 0.46 -3.7±1.45 23.60±3.64 12.17 
P2 142.1±14.15 0.13 -22±2.25 21.10±2.83 10.82 
P3 148.7±17.65 0.68 -24.2±2.93 20.97±1.93 9.27 
P4 535.9±37.8 0.9 2.64±0.94 23.47±1.43 11.78 
P5 726.8±29.31 0.8 13.1±0.59 20.53±1.16 5.23 
P6 334.7±16.4 0.32 21.4±1.89 32.81±1.23 8.32 
P7 480.9±22.2 0.64 15±2.04 22.55±2.15 4.64 
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In vitro release study 
As observed from table 3, only three formulae prepared by modified 
coaservation method were in the nanorange (A1, A2 and A5), while all 
the formulae prepared by the ionotropic  pregelation method (P1-P7) 
were nanodispersions. In vitro release studies were performed for the 
nanodispersions prepared by modified coacervation method (fig. 3) 
and ionotropic pregelation method (fig. 4). 
It is to be noted that, NP dispersions prepared by either methods 
showed a significant retardation in KT release in comparison to the 
commercial eye drops (Acular®). In addition, all the 
nanodispersions showed an initial burst release followed by a more 
gradual and sustained-release phase. The initial fast release of KT 
may be mainly due to the free drug in the nanodispersions and the 
drug adsorbed on the surface of the nanoparticles [22].  
There were no remarkable differences between the release patterns 
of KT from A1, A2 and A5 in the initial phase as shown by their 
MDR0-2h values (table 3), and all showed about 60% release after 6 h, 
this may be attributed to the non-significant differences in 
entrapment efficiencies, as shown in Table 3.  
However, observing the release profiles of nanodispersions prepared 
by ionotropic pregelation method, it is clear that, P1 showed a 
remarkable fast release in the initial phase with the highest MDR0-2h 
(table 4). P1 contains the minimum concentrations of polymers and 
CaCl2, which would probably result in NPs with low density and high 
drug release. On the other hand, the release of KT from P5 and P7 was 
significantly (p>0.05) slow (18-20%) and showed the smallest MDR0-2h 
(table 4). It is worthy to note that, P5 and P7 contain the highest 
concentrations of CaCl2 and CS, respectively, which would increase the 
density of the NPs and delay the diffusion of KT. This result is 
consistent with that of particle size measurements, which indicated 
also that particle core mainly consists of CS and Ca2+ions.  
 
 
Fig. 3: Release profile of KT from ALG/CS nanodispersions 
prepared by modified coaservation method compared to the 
eye drops (Acular®) 
 
Fig. 4: Release profile of KT from ALG/CS nanodispersions 
prepared by ionotropic pregelation method compared to the 
eye drops (Acular®) 
 
Kinetic analysis of release data 
As shown in table 5, the release of KT from all ALG/CS 
nanodispersions (A1, A2 and A5) that were prepared by modified 
coaservation method was best fitted to Korsmeyer-Peppas model 
with n-values less than 0.5 indicating Fickian diffusion mechanism of 
release suggesting that the release was controlled by drug diffusion. 
However, the kinetic data in Table 5 revealed that the release 
from all the ionotropic pregelation formulae (P1-P7) followed 
Korsmeyer-Peppas model with n-values ranged from 0.517 to 
0.833 indicating anomalous (non-Fickian) mechanism, which 
represents a superposition of two mechanisms, and the release 
is controlled by a combination of diffusion and polymer 
relaxation. This is probably because of the formation of a pre-gel 
between alginate and CaCl2. This confirms that each preparation 
method produced particles with different structures and hence 
different physicochemical properties.  
Optimization of the formulations 
According to the physicochemical properties of the ALG/CS 
formulations, ionotropic pregelation method was found to be more 
suitable in the preparation of ALG/CS nanoparticles as all tested 
ALG/CS ratios produced nanodispersions (unlike modified 
coaservation technique) with sustained-release characteristics. 
Among all ionotropic pregelation formulae, P6 was selected as an 
optimum NP dispersion for further investigations as it showed good 
homogeneity (PDI<0.5) and small particle size, which is believed to 
enhance the passage of particles through biological barriers [24]. In 
addition, P6 revealed the highest positive zeta potential, which 
would ensure good muco adhesion and high colloidal stabilization of 
the NPs against coagulation [23]. 
 
Table 5: Kinetic analysis of release data of KT from different ALG/CS nanodispersions prepared by different methods 
Formulation Correlation coefficient (R2) n Release mechanism 
Zero order First order Higuchi model Korsmeyer-peppas 
A1 0.825 0.909 0.907 0.938 0.283 Fickian 
A2 0.880 0.951 0.948 0.960 0.388 Fickian 
A5 0.896 0.953 0.959 0.973 0.367 Fickian 
P1 0.711 0.823 0.852 0.967 0.517 Non-Fickian 
P2 0.773 0.854 0.897 0.995 0.634 Non-Fickian 
P3 0.842 0.918 0.943 0.951 0.534 Non-Fickian 
P4 0.794 0.863 0.909 0.961 0.537 Non-Fickian 
P5 0.987 0.996 0.991 0.998 0.833 Non-Fickian 
P6 0.841 0.91 0.944 0.984 0.552 Non-Fickian 
P7 0.961 0.979 0.988 0.991 0.527 Non-Fickian 
 
FT-IR spectroscopy 
FT-IR was performed to establish the existence of polyelectrolyte 
interaction between ALG and CS and also to confirm the entrapment 
of KT in the nano particulate system. The FT-IR spectra of KT, ALG, 
CS and KT-loaded ALG/CS NPs was demonstrated in fig. 5.  In the 
spectrum of ALG, the bands at 1612.49 and 1417.88 cm-1 are 
assigned to asymmetric and symmetric stretching peaks of 
carboxylate salt groups (COO-), respectively, as shown in fig. 5 (b). In 
fig. 5 (c), the spectrum of CS showed a broad band at 3421 cm-1 
which corresponds to the amine and hydroxyl groups 
bending vibrations of the N-H (N-acetylated residues, amide II band) 
at 1597.06 cm-1. 
Consequently, in the spectrum of NPs, it was observed that the 
asymmetric stretching of COO-groups shifted to 1602.85 
the symmetric stretching of COO-shifted to 1411.89 cm
absorption band of CSat 1597.06 cm-1 of an amide
1570.06 cm-1 after the reaction with ALG, as shown
In the spectrum of pure KT (fig. 5a), peaks were seen at 3346.5 cm
[NH stretch], 3354.21 cm-1 [OH (acid)], 1759.08 cm
(acid)], 1170.79 cm-1 [C = O stretch (diaryl ketone)], 1471.69 cm
and 1431.18 cm-1 [C=C aromatic and aliphatic stretching]. 
Furthermore, peaks at 704.02 cm-1, 731.02 cm-1, 781.17 cm
cm-1 were observed, which confirm the presence of C
(aromatic). The appearance of the characteristic absorption bands of KT 
in the spectrum of KT-loaded ALG/CS NPs indicates that the KT 
molecules were incorporated in the polymeric network (
 
Fig. 5: FT-IR spectroscopy of (a) KT, (b) sodium alginate and (c) 
chitosan (d) KT-loaded ALG/CS nanoparticle
 
Morphological examination 
The ALG/CS nanoparticles appeared to be distinct and spherical, as 
shown in Fig.6.  
However, they were considerably smaller when viewed with TEM in 
comparison to the average particle size observed with 
reported by Parbna et al. that the zetasizer measures the apparent 
size (hydrodynamic radius) of the particle, including 
hydrodynamic layers that are formed around hydrophilic particles 
such as those composed of CS and ALG, leading to an overestimation 
of NP’s size [25]. 
Ex-vivo transcorneal permeation 
Transcorneal permeation of KT from the optimum 
formulation (P6) was significantly (p<0.05) higher than its 
permeation from aqueous solution (Acular® 
same drug concentration (0.5%), as illustrated in fig. 
suggests possible corneal uptake of the NPs due to their small size 
and positive charge [26]. Furthermore, apart from the 
adhesive character of both of ALG and CS polymers, CS is a very 
attractive polymer for ocular drug delivery due to its penetration 
enhancing properties across the mucosal epithelia. 
It was reported that, CS opened the tight junctions located between 
epithelial cells, which resulting in an enhancement of the absorption 
via the para cellular route [27, 28]. In addition, some authors have 
also reported that CS enhances drug penetration through other 
intracellular pathways [29]. 
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Fig. 6: TEM photomicrograph of ALG
 
The transparency of the cornea depends on its hydration status, and 
the corneal hydration value is a sensitive indicator 
corneal tissue irritability in vitro
between 76 and 80%. If the hydration value exceeds 83%,
damages of the epithelium and/or endothelium [30]. Thus, in this 
study the corneal hydration (78.5%) remained in the normal range, 
which indicated that the ALG/CS 
corneal damage. 
 
Fig. 7: Transcorneal permeation of KT from nanodispersion 
(P6) compared to the marketed eye drops (Acular
Stability study 
Stability of nanoparticle dispersions has always been a critical 
determinant for making use of these dispersions as a viable 
alternative to the conventional ophthalmic delivery systems.
The chosen formula P6 was stored at different temperatures (
and 4 °C) and evaluated at specified time intervals 
examination revealed no settling or change in color within the 6 
months. 
NP dispersion showed an increase in particle size, and decrease in 
both pH values and entrapment efficiency w
change with storage was lower at 
they were more stable at lower temperature. Although particles 
increased in size with time, they were still in the nanorange after 6 
months even at 25 °C.  
The decrease in EF% (about 30% at 
leakage of the entrapped drug from the 
attributed to the high solubility of KT in aqueous medium. The pH 
was in the acceptable range before and after storage. 
ophthalmic formulations must be in the pH range between 4.5 and 
11.5 to avoid irritation [31]. 
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Table 6: Evaluation of particle size, pH, and entrapment efficiency of KT nanoparticle dispersion (P6) during storage for 6 months at 4 °C 
and 25 °C (mean±SD, n = 3) 
Parameters Time  
(months) 
P6 
25 °C 4 °C 
Particle size 
(nm) 
0 334.7±16.4 334.7±16.4 
1 454.7±21.1 394.6±17.9 
6 886.8±11.5 574.2±15.3 
pH 0 7 7 
1 6.5 6.8 
6 6.2 6.5 
EF% 0 32.81±1.23 32.81±1.23 
1 29.65±1.8 30.3±1.66 
6 23.4±2.54 28.7±1.85 
 
CONCLUSION 
KT-loaded ALG/CS nanoparticles were successfully prepared under 
mild conditions by two different methods; modified coaservation 
and ionotropic pregelation method. The NPs prepared with 
pregelation method were smaller in size and denser in structure 
with lower entrapment efficiencies. The in vitro release data of all 
the formulations showed a sustained release with the initial burst 
release phase. The TEM image showed that the NPs were distinct 
and spherical. The bioadhesive polymeric nanoparticles can enhance 
the transcorneal permeation of KT in comparison to the 
conventional drug carrier without corneal damage. 
CONFLICT OF INTERESTS 
None Declare 
REFERENCES 
1. Thakur RR, Kashiv M. Modern delivery systems for ocular drug 
formulations: A comparative overview WRT conventional 
dosage form. Int J Res Pharm Biomed Sci 2011;2:8-18. 
2. Prow TW. Toxicity of nanomaterials to the eye. Wiley 
Interdiscip Rev: Nanomed Nanobiotechnol 2010;2:317-33. 
3. Bhattacherjee P. The role of arachidonate metabolites in ocular 
inflammation. Prog Clin Biol Res 1989;312:211-27. 
4. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular 
delivery of NSAIDs. AAPS J 2008;10:229-41. 
5. Hirneiß C, Neubauer AS, Kampik A, Schönfeld C-L. Comparison 
of prednisolone 1%, rimexolone 1% and ketorolac 
tromethamine 0.5% after cataract extraction. Graefes Arch Clin 
Exp Ophthalmol 2005;243:768-73. 
6. Malhotra M, Majumdar DK. In vivo ocular availability of 
ketorolac following ocular instillations of aqueous, oil, and 
ointment formulations to normal corneas of rabbits: A 
technical note. AAPS Pharm Sci Tech 2005;6:523-6. 
7. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative 
effect of 0.5% ketorolac tromethamine solution and 0.1% 
dexamethasone sodium phosphate solution on postsurgical 
blood-aqueous barrier. Arch Ophthalmol 1988;106:480-3. 
8. Heier J, Cheetham JK, DeGryse R, Dirks MS, Caldwell DR, 
Silverstone DE, et al. Ketorolac tromethamine 0.5% ophthalmic 
solution in the treatment of moderate to severe ocular 
inflammation after cataract surgery: A randomized, vehicle-
controlled clinical trial. Am J Ophthalmol 1999;127:253-9. 
9. Fraser-Smith EB, Matthews TR. Effect of ketorolac on 
Pseudomonas aeruginosa ocular infection in rabbits. J Ocul 
Pharmacol Ther 1988;4:101-9. 
10. Fu RC-C, Lidgate DM. In vitro rabbit corneal permeability study 
of ketorolac, tromethamine, a non-steroidal anti-inflammatory 
agent. Drug Dev Ind Pharm 1986;12:2403-30. 
11. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer 
therapy. J Drug Targeting 2008;16:108-23. 
12. Sahoo SK, Labhasetwar V. Nanotech approaches to drug 
delivery and imaging. Drug Discovery Today 2003;8:1112-20. 
13. Calvo P, Vila-Jato JL, Alonso MaJ. Evaluation of cationic 
polymer-coated nanocapsules as ocular drug carriers. Int J 
Pharm 1997;153:41-50. 
14. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro 
evaluation of mucoadhesive properties of chitosan and some 
other natural polymers. Int J Pharm 1992;78:43-8. 
15. Mi F, Sung H, Shyu S. Drug release from chitosan–alginate 
complex beads reinforced by a naturally occurring cross-
linking agent. Carbohydr Polym 2002;48:61-72. 
16. Shah S, Pal A, Kaushik V, Devi S. Preparation and 
characterization of venlafaxine hydrochloride loaded chitosan 
nanoparticles and in vitro release of drug. J Appl Polym Sci 
2009;112:2876-87. 
17. Kulkarni PV, Keshavayya J. Chitosan-sodium alginate 
biodegradable interpenetrating polymer network (IPN) beads 
for delivery of ofloxacin hydrochloride. Int J Pharm Pharm Sci 
2010;2 Suppl 1:77-82. 
18. Sinha V, Singla A, Wadhawan S, Kaushik R, Kumria R, Bansal K, 
et al. Chitosan microspheres as a potential carrier for drugs. Int 
J Pharm 2004;274:1-33. 
19. Rajaonarivony M, Vauthier C, Couarraze G, Puisieux F, Couvreur 
P. Development of a new drug carrier made from alginate. J 
Pharm Sci 1993;82:912-7. 
20. Mohammad pourdounighi N, Behfar A, Ezabadi A, Zolfagharian 
H, Heydari M. Preparation of chitosan nanoparticles containing 
Naja naja oxiana snake venom. Nanomed: Nanotechnol Biol 
Med 2010;6:137-43. 
21. Thwala LN. Preparation and characterization of alginate-
chitosan nanoparticles as a drug delivery system for lipophilic 
compounds. University of Johannesburg; 2012. 
22. Shafie M, Fayek H. Formulation and evaluation of 
betamethasone sodium phosphate loaded nanoparticles for 
ophthalmic delivery. J Clin Exp Ophthalmol 2013;4:1-11. 
23. Challa R, Ahuja A, Ali J, Khar R. Cyclodextrins in drug delivery: 
an updated review. AAPS Pharm Sci Tech 2005;6:329-57. 
24. Ibrahim MM, Abd-Elgawad A-EH, Soliman OA-E, Jablonski MM. 
Natural bioadhesive biodegradable nanoparticles-based topical 
ophthalmic formulations for sustained celecoxib release: In 
vitro study. J Pharm Technol Drug Res 2013;2:1-15. 
25. Prabha S, Zhou W-Z, Panyam J, Labhasetwar V. Size-dependency of 
nanoparticle-mediated gene transfection: studies with fractionated 
nanoparticles. Int J Pharm 2002;244:105-15. 
26. Katara R, Majumdar DK. Eudragit RL 100-based 
nanoparticulate system of aceclofenac for ocular delivery. 
Colloids Surf B 2013;103:455-62. 
27. Schipper NG, Olsson S, Hoogstraate JA, Vårum KM, Artursson P. 
Chitosans as absorption enhancers for poorly absorbable drugs 
2:mechanism of absorption enhancement. Pharm Res 
1997;14:923-9. 
28. Van der Merwe S, Verhoef J, Verheijden J, Kotze A, Junginger H. 
Trimethylated chitosan as polymeric absorption enhancer for 
improved peroral delivery of peptide drugs. Eur J Pharm 
Biopharm 2004;58:225-35. 
29. Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial 
permeability and structure. Int J Pharm 1999;182:21-32. 
30. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone M. 
Effect of iontophoresis on transcorneal permeation ‘in vitro’of 
two β-blocking agents, and on corneal hydration. Int J Pharm 
2003;250:423-9. 
31. Shanmugam S, Ramvignesh T, Sundaramoorthy K, Ayyappan T, 
Vetrichelvan T. Design and evaluation of novel ophthalmic 
delivery system of aciclovir for herpes simplex infection. Res J 
Pharm Dosage Forms Technol 2011;3:52-6. 
 
